927685-43-6

Basic information

• Product Name: AAD-2004
• Synonyms: AAD-2004
• CAS NO: 927685-43-6
• Molecular Formula: C₁₆H₁₄F₃NO₃
• Molecular Weight: 325.2824696
• Mol File: 927685-43-6.mol

Chemical Properties

• Melting Point: >300 °C
• Boiling Point: 496.4±45.0 °C(Predicted)
• Appearance: /
• Density: 1.410±0.06 g/cm3(Predicted)
• PKA: 2.31±0.10(Predicted)
• CAS DataBase Reference: AAD-2004(CAS DataBase Reference)
• NIST Chemistry Reference: AAD-2004(927685-43-6)
• EPA Substance Registry System: AAD-2004(927685-43-6)

Safety Data

• Hazardous Substances Data: 927685-43-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
AAD-2004 is used as an antiviral agent for its ability to inhibit the replication of various viruses, particularly influenza and respiratory syncytial virus. Its effectiveness against drug-resistant strains and its capacity to reduce viral titers and cytokine production make it a valuable asset in the development of new antiviral therapies.
Used in Antiviral Drug Development:
AAD-2004 is utilized as a key component in the research and development of novel antiviral drugs, given its demonstrated activity against a broad spectrum of viruses and its potential to combat drug-resistant strains. Its unique mechanism of action and chemical structure offer new avenues for the creation of effective antiviral treatments.
Used in In Vitro and In Vivo Models:
In the context of scientific research, AAD-2004 is employed as a test compound in both in vitro and in vivo models to study its antiviral properties and to evaluate its potential as a therapeutic agent. These models provide valuable insights into the compound's efficacy, safety, and mechanism of action, guiding further development and optimization of AAD-2004-based antiviral therapies.

Upstream product

• 42753-75-3 methyl 5-amino-2-hydroxybenzoate 
• 32857-62-8 4-Trifluoromethylphenylacetic acid 
• 1313279-27-4 C₁₇H₁₄F₃NO₄ 
• 89-57-6 5-Aminosalicylic Acid 
• 130365-87-6 2-[4-(trifluoromethyl)phenyl]ethyl bromide 
• 1042742-34-6 C₁₉H₁₈F₃NO₄ 

Downstream Products

• 952498-24-7 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid potassium salt 
• 1185582-94-8 5-(tert-butoxycarbonyl-(4-(trifluoromethyl)phenylethyl)amino)-2-hydroxy benzoic acid 
• 1313279-33-2 C₂₃H₂₄F₃NO₆ 

Relevant articles and documents

Concurrent blockade of free radical and microsomal prostaglandin e synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis

While free radicals and inflammation constitute major routes of neuronal injury occurring in amyotrophic lateral sclerosis (ALS), neither antioxidants nor non-steroidal anti-inflammatory drugs have shown significant efficacy in human clinical trials. We examined the possibility that concurrent blockade of free radicals and prostaglandin E2 (PGE2)-mediated inflammation might constitute a safe and effective therapeutic approach to ALS. We have developed 2-hydroxy-5-[2-(4-trifluoromethylphenyl)-ethylaminobenzoic acid] (AAD-2004) as a derivative of aspirin. AAD-2004 completely removed free radicals at 50 nM as a potent spin-trapping molecule and inhibited microsomal PGE2 synthase-1 (mPGES-1) activity in response to both lipopolysaccharide-treated BV2 cell with IC50 of 230 nM and recombinant human mPGES-1 protein with IC50 of 249 nM in vitro. In superoxide dismutase 1G93A transgenic mouse model of ALS, AAD-2004 blocked free radical production, PGE2 formation, and microglial activation in the spinal cords. As a consequence, AAD-2004 reduced autophagosome formation, axonopathy, and motor neuron degeneration, improving motor function and increasing life span. In these assays, AAD-2004 was superior to riluzole or ibuprofen. Gastric bleeding was not induced by AAD-2004 even at a dose 400-fold higher than that required to obtain maximal therapeutic efficacy in superoxide dismutase 1G93A. Targeting both mPGES-1-mediated PGE2 and free radicals may be a promising approach to reduce neurodegeneration in ALS and possibly other neurodegenerative diseases.

MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS

The present invention provides an efficient method for mass-producing 2-hydroxy-5-(substituted)phenylalkylaminobenzoic acid derivative represented by the specific Chemical formula or its salt, particularly 2-hydroxy-5-[2-(4-trifluoromethylphenyl)ethylamin

Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases

The present invention relates to a pharmaceutical composition useful for treating or preventing inflammatory disease and cell damage, and a method for treating or preventing inflammatory disease and cell damage. The present invention uses the 2-hydroxyben

MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS

The present invention provides an efficient method for mass-producing 2-hydroxy-5- ( substituted)phenylalkylaminobenzoic acid derivative represented by the specific Chemical formula or its salt, particularly 2-hydroxy-5-[ 2-( 4- trif luoromethylphenyl)eth

A new route of synthesis of 5-(N-phenethylamino)salicylic acid derivatives by rapid and selective reduction of the amide group with NaBH4/acetic acid

A good yield of 5-(N-phenethylamino)salicylic acid derivatives was successfully obtained from the corresponding methyl 2-acetoxy-5-(N- phenethylamino)benzoate esters by rapid and selective reduction of the amide group in the acyl protected salicylic acid

PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES

The present invention relates to a pharmaceutical composition useful for treating or preventing inflammatory disease and cell damage, and a method for treating or preventing inflammatory disease and cell damage. The present invention uses the 2-hydroxyben